8
Participants
Start Date
July 7, 2017
Primary Completion Date
August 4, 2020
Study Completion Date
August 4, 2020
Cyclophosphamide
Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
Fludarabine
Cohort 1: i.v., 25mg/m2 per day for 5 days
Pembrolizumab
Cohort 1 and 2: i.v., 200mg every 3 weeks
Tumor-Infiltrating Lymphocytes (TILs)
Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
Interleukin-2 (IL-2)
Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
Princess Margaret Cancer Centre, Toronto
Merck Sharp & Dohme LLC
INDUSTRY
University Health Network, Toronto
OTHER